Harvard Bioscience Aktie
WKN: 578107 / ISIN: US4169061052
27.08.2013 18:00:45
|
Harvard Bioscience Hires Jeffrey Duchemin As CEO
(RTTNews) - Harvard Bioscience, Inc. (HBIO) said Tuesday that it has hired veteran life science executive Jeffrey Duchemin as its new Chief Executive Officer.
David Green, who has served as Harvard Bioscience's interim Chief Executive Officer since May 15, has resigned from that interim position and will continue in his capacity as the President of Harvard Bioscience until the completion of the company's spin-off of its regenerative medicine subsidiary.
Prior to joining Harvard Bioscience, Duchemin spent 16 years with Becton Dickinson in progressive sales, marketing and executive leadership positions across its three business segments; BD Medical Systems, BD Diagnostic Systems, and BD Biosciences. In October 2012 BD Biosciences, Discovery Labware was acquired by Corning Life Sciences. Duchemin was a Global Business Director for Corning Life Sciences until his recent departure to Harvard Bioscience.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Harvard Bioscience Inc.mehr Nachrichten
16:05 |
Optimismus in New York: NASDAQ Composite legt zum Handelsstart deutlich zu (finanzen.at) | |
04.04.25 |
Zurückhaltung in New York: NASDAQ Composite bricht schlussendlich ein (finanzen.at) | |
04.04.25 |
NASDAQ Composite aktuell: NASDAQ Composite bricht am Nachmittag ein (finanzen.at) | |
03.04.25 |
Börse New York in Rot: NASDAQ Composite letztendlich tief im Minus (finanzen.at) | |
02.04.25 |
NASDAQ Composite Index-Wert Harvard Bioscience-Aktie: So viel Verlust hätte ein Harvard Bioscience-Investment von vor 5 Jahren eingefahren (finanzen.at) | |
01.04.25 |
Starker Wochentag in New York: NASDAQ Composite nachmittags mit positivem Vorzeichen (finanzen.at) | |
01.04.25 |
NASDAQ Composite-Handel aktuell: NASDAQ Composite am Mittag fester (finanzen.at) | |
01.04.25 |
Börse New York: NASDAQ Composite beginnt die Dienstagssitzung in der Verlustzone (finanzen.at) |
Analysen zu Harvard Bioscience Inc.mehr Analysen
Aktien in diesem Artikel
Harvard Bioscience Inc. | 0,34 | -2,30% |
|